A Study of the Effects of PEITC on Oral Cells With Mutant p53
NCT ID: NCT01790204
Last Updated: 2015-03-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
55 participants
INTERVENTIONAL
2012-02-29
2014-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa
NCT02023931
Oral Green Tea Extract for Small Cell Lung Cancer
NCT01317953
The Safety and Efficacy Test of Nutri-PEITC Jelly in Head and Neck Cancer Patients
NCT03034603
Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer
NCT00064298
Wild Type p53 Adenovirus for Oral Premalignancies
NCT00410865
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Watercress Juice
The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
Watercress Juice
The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Watercress Juice
The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between the ages of 20 and 65
* Must be able to show proof of citizenship or residency of the United States
* Able to sign and understand a standard consent form
Exclusion Criteria
* Having any of the following medical conditions:
* Leukoplakia
* Oral Lesions
* Cancer
* Any oral disease that causes sores, ulcerations, irritations, etc.
* Stomach or Intestinal Ulcers
* IBS (Irritable Bowel Syndrome)
* Kidney Disease
* Allergies to watercress or other Cruciferous Vegetables
* Strict Vegetarians or Vegans
* Religious Consumers of Watercress or other Cruciferous Vegetable Juices
* On any of the following medications:
* Chlorzoxazone (Parafon Forte, Paraflex)
* Lithium
* Water Pills/Diuretics (Thiazide or Lasix)
* Warfarin (Coumadin)
* Vitamin K supplements
* H2 acid blocker (Zantac, Pepcid, Axid, Tagamet)
* Proton Pump Inhibitor (Prevacid)
* Digoxin
* Antibiotics
* Diabetic Medications (Insulin)
* Inhaled Bronchodilator
* Oral Steroids (Prednisone, Medrol)
* Inhaled Steroids (Flonase)
* Raloxifene or Tamoxifen
* Thyroid Hormone Replacement
20 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Georgetown University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fung-Lung Chung, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Lombardi Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Georgetown Clinical Research Unit
Washington D.C., District of Columbia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R01CA1000853
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.